Cancer-associated fibroblasts—heroes or villains?

Krystyna A. Gieniec, Lisa Butler, Dan Worthley, Susan L. Woods

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Cancer-associated fibroblasts (CAFs) were originally presumed to represent a homogeneous population uniformly driving tumorigenesis, united by their morphology and peritumoural location. Our understanding of CAFs has since been shaped by sophisticated in vitro and in vivo experiments, pathological association and, more recently, ablation, and it is now widely appreciated that CAFs form a group of highly heterogeneous cells with no single overarching marker. Studies have demonstrated that the CAF population contains different subtypes based on the expression of marker proteins with the capacity to promote or inhibit cancer, with their biological role as accomplices or adversaries dependent on many factors, including the cancer stage. So, while CAFs have been endlessly shown to promote the growth, survival and spread of tumours via improvements in functionality and an altered secretome, they are also capable of retarding tumorigenesis via largely unknown mechanisms. It is important to reconcile these disparate results so that the functions of, or factors produced by, tumour-promoting subtypes can be specifically targeted to improve cancer patient outcomes. This review will dissect out CAF complexity and CAF-directed cancer treatment strategies in order to provide a case for future, rational therapies.

LanguageEnglish
Pages293-302
Number of pages10
JournalBritish Journal of Cancer
Volume121
Issue number4
DOIs
Publication statusPublished - 13 Aug 2019

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Gieniec, Krystyna A. ; Butler, Lisa ; Worthley, Dan ; Woods, Susan L. / Cancer-associated fibroblasts—heroes or villains?. In: British Journal of Cancer. 2019 ; Vol. 121, No. 4. pp. 293-302.
@article{e17853f157f94ba3b951a163c87fa4da,
title = "Cancer-associated fibroblasts—heroes or villains?",
abstract = "Cancer-associated fibroblasts (CAFs) were originally presumed to represent a homogeneous population uniformly driving tumorigenesis, united by their morphology and peritumoural location. Our understanding of CAFs has since been shaped by sophisticated in vitro and in vivo experiments, pathological association and, more recently, ablation, and it is now widely appreciated that CAFs form a group of highly heterogeneous cells with no single overarching marker. Studies have demonstrated that the CAF population contains different subtypes based on the expression of marker proteins with the capacity to promote or inhibit cancer, with their biological role as accomplices or adversaries dependent on many factors, including the cancer stage. So, while CAFs have been endlessly shown to promote the growth, survival and spread of tumours via improvements in functionality and an altered secretome, they are also capable of retarding tumorigenesis via largely unknown mechanisms. It is important to reconcile these disparate results so that the functions of, or factors produced by, tumour-promoting subtypes can be specifically targeted to improve cancer patient outcomes. This review will dissect out CAF complexity and CAF-directed cancer treatment strategies in order to provide a case for future, rational therapies.",
author = "Gieniec, {Krystyna A.} and Lisa Butler and Dan Worthley and Woods, {Susan L.}",
year = "2019",
month = "8",
day = "13",
doi = "10.1038/s41416-019-0509-3",
language = "English",
volume = "121",
pages = "293--302",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "4",

}

Cancer-associated fibroblasts—heroes or villains? / Gieniec, Krystyna A.; Butler, Lisa; Worthley, Dan; Woods, Susan L.

In: British Journal of Cancer, Vol. 121, No. 4, 13.08.2019, p. 293-302.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Cancer-associated fibroblasts—heroes or villains?

AU - Gieniec, Krystyna A.

AU - Butler, Lisa

AU - Worthley, Dan

AU - Woods, Susan L.

PY - 2019/8/13

Y1 - 2019/8/13

N2 - Cancer-associated fibroblasts (CAFs) were originally presumed to represent a homogeneous population uniformly driving tumorigenesis, united by their morphology and peritumoural location. Our understanding of CAFs has since been shaped by sophisticated in vitro and in vivo experiments, pathological association and, more recently, ablation, and it is now widely appreciated that CAFs form a group of highly heterogeneous cells with no single overarching marker. Studies have demonstrated that the CAF population contains different subtypes based on the expression of marker proteins with the capacity to promote or inhibit cancer, with their biological role as accomplices or adversaries dependent on many factors, including the cancer stage. So, while CAFs have been endlessly shown to promote the growth, survival and spread of tumours via improvements in functionality and an altered secretome, they are also capable of retarding tumorigenesis via largely unknown mechanisms. It is important to reconcile these disparate results so that the functions of, or factors produced by, tumour-promoting subtypes can be specifically targeted to improve cancer patient outcomes. This review will dissect out CAF complexity and CAF-directed cancer treatment strategies in order to provide a case for future, rational therapies.

AB - Cancer-associated fibroblasts (CAFs) were originally presumed to represent a homogeneous population uniformly driving tumorigenesis, united by their morphology and peritumoural location. Our understanding of CAFs has since been shaped by sophisticated in vitro and in vivo experiments, pathological association and, more recently, ablation, and it is now widely appreciated that CAFs form a group of highly heterogeneous cells with no single overarching marker. Studies have demonstrated that the CAF population contains different subtypes based on the expression of marker proteins with the capacity to promote or inhibit cancer, with their biological role as accomplices or adversaries dependent on many factors, including the cancer stage. So, while CAFs have been endlessly shown to promote the growth, survival and spread of tumours via improvements in functionality and an altered secretome, they are also capable of retarding tumorigenesis via largely unknown mechanisms. It is important to reconcile these disparate results so that the functions of, or factors produced by, tumour-promoting subtypes can be specifically targeted to improve cancer patient outcomes. This review will dissect out CAF complexity and CAF-directed cancer treatment strategies in order to provide a case for future, rational therapies.

UR - http://www.scopus.com/inward/record.url?scp=85068706554&partnerID=8YFLogxK

U2 - 10.1038/s41416-019-0509-3

DO - 10.1038/s41416-019-0509-3

M3 - Review article

VL - 121

SP - 293

EP - 302

JO - British Journal of Cancer

T2 - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 4

ER -